Part 1 : Lipoprotein Metabolism, Qualitative Changes and Measurements -- 1. Laboratory Assessment of Lipoproteins in Type 2 Diabetes -- 2. Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus -- 3. Links Between Glucose and Lipoproteins -- 4. Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes -- 5. Lipoprotein metabolism and alterations induced by insulin resistance and diabetes -- 6. The PPAR system in diabetes -- 7. Production And Metabolism Of Triglyceride-Rich Lipoproteins: Impact Of Diabetes -- 8. Triglyceride- And Cholesterol-Rich Remnant Lipoproteins In Risk Of Cardiovascular Disease In Diabetes Mellitus -- 9. HDL Function In Diabetes -- 10. Lipoprotein (a): Metabolism, Pathophysiology and Impact on Diabetes Mellitus -- 11. Lipoprotein Glycation in Diabetes Mellitus -- 12. Lipid:Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes -- Part 2 : Lipoproteins and the Complications of Diabetes -- 13. The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes -- 14. Endothelial dysfunction in type 2 diabetes, with an update on new interventions -- 15. Lipoproteins and diabetic kidney disease -- 16. Lipids and Diabetic Retinopathy -- 17. Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy -- 18. The Role Of Lipids And Lipoproteins In Peripheral Neuropathy -- 19. Lipoproteins and Ischemic Stroke in Diabetes -- Part 3 : Lipoprotein Treatment in Diabetes -- 20. About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus -- 21. Effects of Lifestyle (Diet, Plant Sterols, Exercise and Smoking) and Glycemic Control on Lipoproteins in Diabetes -- 22. Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes -- 23. Statin intolerance - An overview for clinicians -- 24. Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2 -- 25. EPA and Mixed Omega-3 Fatty Acids: Impact on Dyslipidemia and Cardiovascular Events in Patients With Diabetes -- 26. Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus -- 27. Clinical Efficacy Of Proprotein Convertase Synthase Kexin Type 9 Inhibition In Persons With Diabetes Mellitus -- 28. Clinical Care of Lipids in People with Type 1 diabetes -- 29. Adjunct drug treatment to reduce vascular disease in people with diabetes -- 30. Emerging lipoprotein-related therapeutics for patients with diabetes -- Part 4 : Epidemiology of Diabetes and Diabetic Dyslipidemia -- 31. Diabetes Epidemiology And Its Implications -- 32. Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes.